timothy sykes logo
RXRX Stock Grinds Higher As Traders Study Biotech Runway Thumbnail
G Google News

RXRX Stock Grinds Higher As Traders Study Biotech Runway

TIM SYKES•UPDATED OCT. 7, 2026, 3:02 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Recursion Pharmaceuticals Inc. stocks have been trading down by -4.43 percent after AI drug-discovery partnership concerns spooked investors.

Key Takeaways

  • RXRX has pushed from the low $3s to mid-$4s over recent weeks, showing steady accumulation on the daily chart.
  • The company sits on roughly $556.8M in cash with low debt, giving Recursion Pharmaceuticals Inc. room to fund heavy R&D.
  • RXRX posts deep losses and negative margins, keeping it firmly in high-risk, high-reward territory for active traders.
  • Tight intraday trading between $4.30–$4.45 signals short-term consolidation after a strong multi-day push.

Candlestick Chart

Live Update At 15:02:24 EDT: On Wednesday, October 07, 2026 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending down by -4.43%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

RXRX is a classic high-burn biotech story with a long runway and big losses. Recursion Pharmaceuticals Inc. generated about $74.3M in revenue over the trailing period, but that small top line sits against heavy spending. Recent quarterly data shows revenue of only about $7.3M while RXRX booked a net loss of roughly $131M, or about -$0.25 per share. That translates into brutal profit margins and negative returns on equity and assets.

The flip side is balance-sheet strength. Recursion Pharmaceuticals Inc. reports around $545.7M in cash and equivalents and roughly $556.8M in total cash at quarter end, with total debt only in the single‑digit millions. Current and quick ratios near 5 show RXRX is far from a liquidity crunch.

More Breaking News

Valuation is rich on a sales basis, with a price-to-sales ratio above 47 and price-to-book near 2.8. That tells traders the market is paying up for Recursion Pharmaceuticals Inc.’s platform and pipeline optionality rather than current income. For active traders, RXRX is all about momentum, dilution risk, and timing entries around support and resistance, not about classic value metrics.

Why Traders Are Watching RXRX Price Action

RXRX has been quietly building a trend that short-term traders should not ignore. On the daily chart, Recursion Pharmaceuticals Inc. moved from about $3.19 on 2026/09/16 to recent closes around $4.42 on 2026/10/07. That’s roughly a 38% run in just a few weeks. The climb has not been straight up. RXRX pulled back to the mid‑$3s several times, but each dip found buyers, showing underlying demand.

Look closer at the recent days. Recursion Pharmaceuticals Inc. bounced from the $3.70–$3.90 area in late September to over $4.70 on 2026/10/05 before easing back toward the mid‑$4s. That type of extension, then cooling off, is textbook for momentum names. RXRX traders who chase breakouts without a plan often get chopped up on these retraces.

Intraday, RXRX shows tight action. Most 5‑minute candles on the latest day stick between roughly $4.30 and $4.45 after an early morning pop over $4.50. That coiling behavior suggests Recursion Pharmaceuticals Inc. is digesting gains. For day traders, that means clear levels: support near $4.30, resistance around $4.50–$4.60. A strong push through either side can trigger the next move.

The key is context. RXRX is burning over $100M in cash per quarter, yet it still holds more than half a billion dollars. Recursion Pharmaceuticals Inc. has room to keep funding research, but the market knows more capital raises are possible down the road. That’s why RXRX trades like a sentiment and catalyst vehicle, not a steady compounder. Nimble traders study the chart, respect the risk, and plan exits.

Conclusion

RXRX sits at the intersection of big biotech dreams and harsh financial reality. Recursion Pharmaceuticals Inc. is posting serious quarterly losses — over $130M — and its margins are deeply negative. At the same time, RXRX has a fortress-like cash position for a small-cap name and minimal leverage, giving the company years of operational runway if it maintains a similar burn. That combination fuels the speculative energy around Recursion Pharmaceuticals Inc.

On the tape, RXRX has already delivered a meaningful percentage move off the September lows. Recursion Pharmaceuticals Inc. is now consolidating in the mid‑$4s, a zone where late longs may be trapped and patient traders wait for the next clean setup. A break above recent highs near $4.90 can attract fresh momentum trading, while a failure of support near the low $4s opens the door for a deeper pullback toward prior bases.

This is where discipline matters. As Tim Sykes often says, “The market doesn’t care about your opinion, only your risk management.” As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.”. RXRX is a prime example. Recursion Pharmaceuticals Inc. offers big upside swings, but the financials make clear it is not a low-risk story. Traders focusing on RXRX should map their levels, size positions conservatively, and be ready to cut losses fast if the chart rolls over. This content is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”